NCT03409614 2025-03-13Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerRegeneron PharmaceuticalsPhase 3 Completed790 enrolled 1 FDA